Global Specialty Sales
$296M
+26.1% YoY
Includes $20M milestone from Almirall; ex-milestone growth was 24.2%.
SUNPHARMA
Healthcare
23 Jan 2024
Sunpharma Ltd — Q3 FY24
Sun Pharma reported Q3 FY24 consolidated revenue of INR 12,157 crore, up 9.5% YoY, driven by strong specialty sales (up 26.1% to $296M) and India formulation growth of 11.4%.
Financial stats pending filing verification
2-Minute Summary
✦ AI-Generated from Full Transcript
Sun Pharma reported Q3 FY24 consolidated revenue of INR 12,157 crore, up 9.5% YoY, driven by strong specialty sales (up 26.1% to $296M) and India formulation growth of 11.4%. EBITDA margin expanded 140bps to 28.1%, aided by better product mix and lower material costs. Adjusted PAT grew 19.7% to INR 2,594 crore. U.S. specialty continued to perform well, though generic business remained flattish due to Halol/Mohali plant issues. Management highlighted a healthy pipeline, including Nidlegy filing in Europe and Phase II/III starts for MM-II and GL0034 in H2 2024. The Taro merger at $43/share offers strategic benefits. Key risk: ongoing regulatory challenges at Mohali plant may delay generic supply recovery.
सन फार्मा ने तीसरी तिमाही में 12,157 करोड़ रुपये की कमाई की, जो पिछले साल से 9.5% ज़्यादा है। इसकी वजह खास दवाओं की बिक्री (26.1% बढ़कर 296 मिलियन डॉलर) और भारत में दवा बिक्री (11.4% बढ़ोतरी) है। कंपनी का मुनाफा 28.1% बढ़ा, क्योंकि उसने सस्ते कच्चे माल का इस्तेमाल किया और बेहतर उत्पाद बेचे। शुद्ध मुनाफा 19.7% बढ़कर 2,594 करोड़ रुपये हुआ। अमेरिका में खास दवाएं अच्छा कर रही हैं, लेकिन सस्ती दवाओं का कारोबार फैक्ट्री की समस्याओं के कारण सपाट रहा। कंपनी ने यूरोप में नई दवा फाइल करने और 2024 में दो नई दवाओं के परीक्षण शुरू करने की योजना बनाई है। टैरो कंपनी को 43 डॉलर प्रति शेयर पर खरीदने से फायदा होगा। लेकिन मोहाली फैक्ट्री पर नियामकीय चुनौतियां सस्ती दवाओं की आपूर्ति में देरी कर सकती हैं।
Key Numbers
India Market Share
8.51%
+5bps YoY
Sun Pharma ranked #1 in IPM with 8.51% share as per AIOCD AWACS MAT Dec'23.
U.S. Formulation Sales
$477M
+13.2% YoY
Growth driven by specialty; partially offset by Halol/Mohali generic issues.
R&D Spend as % of Sales
6.8%
N/A
Consolidated R&D at INR 8,245M; specialty R&D accounted for 39.2% of total.
What Changed vs Last Quarter
NEW
R&D spend to touch lower end of 7% guidance for FY24
Management indicated that R&D spend for the full year is expected to reach the lower end of the 7% of sales guidance.
NEW
Phase II/III trials for MM-II and GL0034 to start in H2 2024
Phase III for MM-II and Phase II for GL0034, initially expected early 2024, are now slated to begin in the second half of 2024.
NEW
Nidlegy filing with European authorities in H1 2024
Partner product Nidlegy is expected to be filed with European authorities during the first half of 2024.
DROPPED
R&D spend guidance maintained
Management expects R&D expenses to remain at similar levels or increase due to clinical trial ramp-up.
DROPPED
India business to grow higher than market
Management aims to grow India formulation business faster than the Indian pharmaceutical market on an annualized basis.
DROPPED
Tax rate to inch up on annual basis
Tax rate expected to be higher than last year's 8.8% due to profit mix across jurisdictions.
NEW RISK
Mohali plant supply constraints persist
Supplies from Mohali plant are not normal; issues with product prioritization and quality clearances are causing delays.
NEW RISK
CEQUA facing increased competition in dry eye space
CEQUA's market share has declined due to generic Restasis and new entrants with different mechanisms of action.
NEW RISK
Red Sea supply chain disruption risk
Management is monitoring the Red Sea situation; potential for shipment delays if situation does not normalize.
NEW RISK
Taro merger may not receive minority approval
The $43/share offer requires approval from Taro's minority shareholders; failure could derail the merger.
RISK GONE
Halol plant remediation uncertainty
Halol plant remains under FDA scrutiny; no timeline for re-inspection or resolution, impacting US generic supply.
RISK GONE
Taro Israel operations exposure
Taro's operations in Israel may be impacted by regional conflict, though management says business continuity is maintained.
RISK GONE
US generic pricing pressure
Management sees no significant improvement in generic pricing environment; pricing remains product-specific and competitive.
🤫 Topics management stopped discussing
Mentioned in Q1 FY24, Q2 FY24
Management aims to grow India formulation business faster than the Indian pharmaceutical market on an annualized basis.
Management Guidance
R&D spend to touch lower end of 7% guidance for FY24
Management indicated that R&D spend for the full year is expected to reach the lower end of the 7% of sales guidance.
Management guidance otherPhase II/III trials for MM-II and GL0034 to start in H2 2024
Phase III for MM-II and Phase II for GL0034, initially expected early 2024, are now slated to begin in the second half of 2024.
Management guidance growthNidlegy filing with European authorities in H1 2024
Partner product Nidlegy is expected to be filed with European authorities during the first half of 2024.
Management guidance growthKey Risks
Mohali plant supply constraints persist
Supplies from Mohali plant are not normal; issues with product prioritization and quality clearances are causing delays.
high · management_commentaryCEQUA facing increased competition in dry eye space
CEQUA's market share has declined due to generic Restasis and new entrants with different mechanisms of action.
medium · analyst_questionRed Sea supply chain disruption risk
Management is monitoring the Red Sea situation; potential for shipment delays if situation does not normalize.
medium · analyst_questionTaro merger may not receive minority approval
The $43/share offer requires approval from Taro's minority shareholders; failure could derail the merger.
high · management_commentaryNotable Quotes
Generic REVLIMID sales were very small in this quarter.
If you see any IL-23 and ILUMYA also, there is a good mix of treatment-naive patients who get onto the product, along with almost an equal proportion of patients who have failed on some other product before they come on to ours.
We believe that with our overall performance that we've seen in healthy subjects for our product, it has a compelling therapeutic efficacy likely to be there when the product comes to market.
Frequently Asked Questions
What was Sunpharma's revenue in Q3 FY24?
Sunpharma reported revenue of ₹12,157 Cr in Q3 FY24, representing a +9.5% change compared to the same quarter last year.
What guidance did Sunpharma management give for FY25?
R&D spend to touch lower end of 7% guidance for FY24: Management indicated that R&D spend for the full year is expected to reach the lower end of the 7% of sales guidance. Phase II/III trials for MM-II and GL0034 to start in H2 2024: Phase III for MM-II and Phase II for GL0034, initially expected early 2024, are now slated to begin in the second half of 2024. Nidlegy filing with European authorities in H1 2024: Partner product Nidlegy is expected to be filed with European authorities during the first half of 2024.
What are the key risks for Sunpharma in FY25?
Key risks include Mohali plant supply constraints persist — Supplies from Mohali plant are not normal; issues with product prioritization and quality clearances are causing delays.; CEQUA facing increased competition in dry eye space — CEQUA's market share has declined due to generic Restasis and new entrants with different mechanisms of action.; Red Sea supply chain disruption risk — Management is monitoring the Red Sea situation; potential for shipment delays if situation does not normalize.; Taro merger may not receive minority approval — The $43/share offer requires approval from Taro's minority shareholders; failure could derail the merger..
Did Sunpharma meet its previous quarter's guidance?
Of 1 tracked promise, management 0 met, 0 close, 1 missed.
Where can I read the full Sunpharma Q3 FY24 concall transcript?
The full earnings conference call transcript or source release is available on the linked source material. This page provides an AI-generated summary with filing verification status shown on the financial stats.